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Abstract
Exposure to toxaphene, an environmentally persistent mixture of chlorinated terpenes previously utilized as an
insecticide, has been associated with various cancers and diseases such as amyotrophic lateral sclerosis.
Nevertheless, the cellular and molecular mechanisms responsible for these toxic effects have not been established.
In this study, we used a functional approach in the model eukaryote Saccharomyces cerevisiae to demonstrate that
toxaphene affects yeast mutants defective in (1) processes associated with transcription elongation and (2) nutrient
utilization. Synergistic growth defects are observed upon exposure to both toxaphene and the known transcription
elongation inhibitor mycophenolic acid (MPA). However, unlike MPA, toxaphene does not deplete nucleotides and
additionally has no detectable effect on transcription elongation. Many of the yeast genes identified in this study have
human homologs, warranting further investigations into the potentially conserved mechanisms of toxaphene toxicity.
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Introduction
Toxaphene is a complex mixture of polychlorinated
camphenes and bornanes primarily used to control insects on
cotton during the 1960-80s (Figure 1A) [1]. After the ban of
DDT in 1972, toxaphene became the most heavily applied
pesticide in the United States, but all registered uses were
cancelled by the U.S. Environmental Protection Agency (EPA)
in 1989 over concerns related to its toxicity and persistence [2].
Today, toxaphene remains a problematic environmental
contaminant, ranking 32nd on the Agency for Toxic Substances
and Disease Registry (ATSDR) Priority List of Hazardous
Substances, a list of compounds that possibly threaten human
health via their toxicity and possibility for exposure at EPA
National Priorities List hazardous waste sites. Toxaphene's
most persistent congeners and degradation products have
been detected in water, air, and sediment, and are known to
bioaccumulate in wildlife and humans [1]. Animal studies have
deemed toxaphene a neuro-, nephro-, immuno-, and
hepatotoxicant, an endocrine disruptor, and a carcinogen, with
the International Agency for Research on Cancer (IARC)
classifying toxaphene as Group 2B (possibly carcinogenic to
humans) [1,3]. Epidemiological analyses have linked
toxaphene to leukemia [4], non-Hodgkin's lymphoma [5],
melanoma [6], and more recently, amyotrophic lateral sclerosis
[7]. However, the cellular and molecular processes that
toxaphene perturbs to result in these toxicities and disease
states remain unclear.
The eukaryotic yeast Saccharomyces cerevisiae is a
valuable model in which to conduct toxicological studies. First,
basic cellular processes, along with metabolic and signaling
pathways, are conserved to higher organisms. Second, a close
human homolog has been identified for a significant portion of
yeast genes, with several hundred of the conserved genes
linked to disease in humans [8]. Finally, the availability of
deletion mutant collections, overexpression libraries, and
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e81253
genetic and physical interaction data provide unmatched
resources for inquiries into potential cellular and molecular
mechanisms of toxicity. With the deletion mutant collection [9],
functional toxicogenomic analyses (also known as functional
profiling) can be conducted by examining, in parallel, the
sensitivity or resistance of each mutant strain to a compound of
interest. Such investigations, through the identification of yeast
genes required for chemical tolerance, have discovered
molecular mechanisms for numerous drugs and toxicants
[10,11], with several studies confirming results in human cells
[12-14].
Here we present the results of a functional screen devised to
identify yeast genes necessary for growth in the presence of
toxaphene. It is the first known genome-wide study in any
organism to examine the genetic requirements for toxaphene
tolerance. Our results demonstrate that similar to the known
transcription elongation inhibitors mycophenolic acid (MPA)
and 6-azauracil (6-AU), mutants defective in processes linked
to transcription elongation are sensitive to toxaphene. While
toxaphene does display synergism with MPA, it apparently
exhibits a mechanism of action distinct from that of MPA/6-AU
and additionally does not appear to directly affect transcription
elongation. Many yeast genes required for toxaphene
resistance have human homologs that may play a role in
human toxicity.
Materials and Methods
Yeast strains and culture
The diploid non-essential yeast deletion strains used for
functional profiling and confirmation analyses were of the
BY4743 background (MATa/MATα his3Δ1/his3Δ1 leu2Δ0/
leu2Δ0 lys2Δ0/LYS2 MET15/met15Δ0 ura3Δ0/ura3Δ0, Life
Technologies). Yeast growth was performed in liquid rich
media (1% yeast extract, 2% peptone, 2% dextrose, YPD) at
30°C with shaking at 200 revolutions per minute (rpm). For the
elongation assays, the GAL1-YLR454 strain [15] was grown in
rich media containing galactose (1% yeast extract, 2%
peptone, 2% galactose, YPGal).
Dose-finding and growth curve assays
Dose-finding and growth curves were performed as in [16].
Toxaphene and MPA (Sigma Aldrich) solutions were prepared
in dimethylsulfoxide (DMSO) and added to the desired final
concentrations (1% or less by volume) with at least three
technical replicates per dose. The area means and standard
error (SE) for the growth of each strain (as measured by the
area under the curve) was derived from three independent
cultures.
Functional profiling of the yeast genome
The functional screen and differential strain sensitivity
analysis (DSSA) were performed as previously described [17].
Briefly, pools of deletion mutants (n = 4607) were cultured for
15 generations in YPD at various toxaphene concentrations.
Following extraction of genomic DNA with the YDER kit (Pierce
Biotechnology), DNA sequences unique to each strain were
amplified by PCR and subsequently hybridized to TAG4 arrays
(Affymetrix). Arrays were incubated overnight, stained, and
scanned at 560 nm with a GeneChip Scanner (Affymetrix).
Data files are available at the Gene Expression Omnibus
database (http://www.ncbi.nlm.nih.gov/geo/).
Over-enrichment and network mapping analyses
The Functional Specification (FunSpec) resource [18]
identified significantly overrepresented Gene Ontology (GO)
and MIPS (Munich Information Center for Protein Sequences)
Figure 1.  Determining the toxaphene IC20 for functional profiling.  (A) The structure of two chlorinated congeners present in
the toxaphene technical mixture. (B) Representative growth curves in YPD media for the BY4743 wild-type strain treated with
toxaphene. For clarity, only the 250, 550, and 1000μM toxaphene doses are shown, although additional curves were performed at
400, 700, and 850μM. (C) The area under the curve (AUC) was calculated at each dose for three independent experiments,
expressed as the mean and SE, and plotted as a percentage of the untreated control. The toxaphene IC20 was determined to be
640μM, as indicated by the dashed lines.
doi: 10.1371/journal.pone.0081253.g001
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categories within the DSSA data using a p value cutoff of 0.002
and Bonferroni correction. Gene interaction networks were
generated in Cytoscape [19] by mapping fitness scores for
toxaphene-sensitive strains onto the BioGrid Saccharomyces
cerevisiae functional interaction network. The jActiveModules
Cytoscape plugin identified sub-networks enriched with fitness
data, within which the BiNGO plugin discovered
overrepresented GO categories.
Analysis of relative strain growth by flow cytometry
Analyses of relative strain growth were performed as
described [16]. Briefly, green fluorescent protein (GFP)-tagged
wild-type and untagged deletion strains were mixed in
approximately equal numbers and cultured for 24 hours at
30°C in the presence of toxaphene. At least 20,000 cells were
analyzed at T=0 and T=24 hours using a FACSCalibur flow
cytometer. A ratio of growth was calculated for untagged cells
in treated versus untreated samples using the percentages of
wild-type GFP and untagged mutant cells present. Statistically
significant differences between the means of three independent
DMSO-treated and toxaphene-treated cultures were
determined with Student’s t-test.
Analyses of transcription elongation
Gene Length Accumulation of mRNA (GLAM) assays were
performed as described [20]. Chromatin immunoprecipitation
experiments were performed as described [21], except mouse
monoclonal anti-Rpb3 (1Y26, Abcam) antibody was used.
Immunoprecipitated DNA was measured by quantitative PCR
in a LightCycler (Roche), using the primers listed in Table S1.
Normalizations required for RNA polymerase II processivity
comparisons were applied as described [15].
Results
Functional profiling in yeast identifies genes required
for toxaphene tolerance
The IC20, the concentration at which growth is inhibited by
20%, is a dose frequently utilized in functional screens, as it
elicits a response without being overly toxic [17]. After
performing growth curve analyses for wild-type yeast treated
with increasing concentrations of toxaphene (Figure 1B), the
toxaphene IC20 was calculated as 640μM (Figure 1C). Pools of
yeast homozygous diploid deletion mutants (n = 4607) were
grown for 15 generations at the toxaphene IC20 (640μM), 50%
IC20 (320μM), and 25% IC20 (160μM) to identify genes
important for growth in toxaphene. DSSA deemed 130 strains
sensitive and 542 strains resistant to at least one dose of
toxaphene (Table S2). Sensitive strains were the focus of this
study, with the top 30 displaying growth defects shown in Table
1.
Overrepresentation analyses identify biological
attributes needed for toxaphene resistance
All toxaphene-sensitive strains identified by DSSA (n = 122;
Table S2) were analyzed with FunSpec for significantly
overrepresented biological attributes at a corrected p value of
0.002 (Table 2). Transcription elongation and aerobic
respiration were enriched in both GO and MIPS categories,
indicating that mutants lacking genes associated with these
processes are sensitive to toxaphene. Other overrepresented
GO classifications included mitochondrial respiratory chain
complex IV biogenesis and aromatic amino acid biosynthesis.
To supplement the FunSpec evaluation, network mapping was
performed with Cytoscape to identify additional attributes
required for toxaphene tolerance. The BiNGO plugin revealed
that transcription elongation, aerobic respiration, and aromatic
amino acid biosynthesis were overrepresented within the
network data (Figure 2). Other categories uncovered were cell
death and metabolic salvage.
Mutants defective in transcription elongation
associated processes are sensitive to toxaphene
FunSpec and Cytoscape analyses indicated enrichment of
transcription elongation mutants within the functional profiling
data. Accordingly, growth curves were obtained for the
transcription elongation mutants identified in the screen and
compared to the BY4743 wild-type strain, with five out of the
six (cdc73Δ, dst1Δ , mft1Δ, thp2Δ, and spt4Δ, but not elf1Δ)
confirmed as sensitive to toxaphene (Figure 3). Considering
two of these mutants (mft1Δ and thp2Δ) lacked components of
THO, a complex required for efficient transcription elongation
[22] and mRNA export [23], we tested strains harboring
deletions of the two additional THO subunits (hpr1Δ and
tho2Δ), finding growth defects (Figure 3). Many of these
confirmed strains are also sensitive to the transcription
elongation inhibitors MPA and 6-AU (Table S3) [24], therefore,
we examined whether toxaphene affected a set of MPA- or 6-
AU-sensitive mutants known to exhibit transcription elongation
defects. Indeed, strains lacking subunits of the SAGA histone
acetyltransferase (spt20Δ), the Paf1p complex (rtf1Δ), and the
TREX-2 transcriptional export machinery (sac3Δ and thp1Δ)
were sensitive to toxaphene (Figure 3). Additionally, a gene
encoding an RNA polymerase II subunit (RPB9), along with
genes implicated in RNA polymerase II activation (CTK3,
RAD6, and SNF6) or reactivation through deubiquitylation
(BRE5 and UBP3) were required for toxaphene tolerance
(Figure 3).
Nitrogen utilization and aromatic amino acid
biosynthesis mutants are sensitive to toxaphene
The dal81Δ, stp1Δ, and ure2Δ nitrogen utilization mutants
identified in the functional screen (Table 1) were confirmed by
growth curve analyses to exhibit severe growth defects in
presence of toxaphene (Figure 4). For unknown reasons, the
growth of these mutants is also hindered by the transcription
elongation inhibitors MPA and 6-AU [24,25]. Additionally, in
agreement with enrichment analyses (Figure 2 and Table 2),
mutants deficient in aromatic amino acid biosynthesis were
toxaphene-sensitive, with the TRP4 tryptophan biosynthesis
gene implicated as the pathway component furthest
downstream (Figure 4). However, neither tryptophan
supplementation of YPD media nor titration into defined media
altered growth of the BY4743 wild-type strain in toxaphene
(data not shown).
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Toxaphene exhibits synergy with MPA, but its
mechanism of action is not similar
Similarities between the mutant sensitivity profiles for
toxaphene and the transcription elongation inhibitors MPA and
6-AU (Table S3) prompted us to examine whether the
compounds shared a mechanism of action. Both MPA and 6-
AU inhibit the guanosine monophosphate (GMP) synthesis
enzyme inosine monophosphate dehydrogenase (IMPDH),
which reduces ribonucleotide levels and increases dependence
on transcription elongation factors for transcriptional efficiency
[26,27]. As a first step, we assessed synergy between
toxaphene and MPA by obtaining growth curves for each
condition as well as the mixture. We also considered 4-
nitroquinoline-N-oxide (4-NQO), a model carcinogen whose
DNA adducts may be repaired by transcription-coupled
nucleotide excision repair [25], and tunicamycin, an
endoplasmic reticulum stressor [28]. Both MPA and 4-NQO
displayed additive inhibitory growth effects with toxaphene,
while the general stressor tunicamycin did not (Figure 5).
Second, we examined whether guanine or uracil
supplementation could reverse toxaphene sensitivity, as both
can rescue the growth of transcription elongation mutants in
the presence of either MPA or 6-AU [24,26]. A flow cytometry
assay, in which relative growth of a mutant strain to a wild-type
GFP-expressing strain was compared under the indicated
conditions, confirmed that neither guanine nor uracil reversed
toxaphene sensitivity of transcription elongation mutants
(Figures 6A and B). Third, we tested a strain deleted for IMD2,
the only yeast IMPDH homologue that provides resistance to
MPA [29], for toxaphene sensitivity. Although hypersensitive to
MPA, the imd2Δ strain did not display altered growth in
Table 1. Fitness scores for the top 30 deletion strains identified as significantly sensitive to toxaphene after 15 generations of
growth.
 Log2 values   
Deleted Gene 25% IC20 160μM 50% IC20 320μM 100%IC20 640μM Function of deleted gene Confirmed
PDR5 -6.30 -5.80 -6.05 Plasma membrane multidrug transporter S
RPN4 -3.15 -3.05 -2.55 Transcription factor; stimulates expression of proteasome genes S
DAL81 -3.10 -3.50 -3.00 Positive regulator of genes in nitrogen degradation pathways S
TRP4 -2.90 -4.50 -4.70 Anthranilate phosphoribosyl transferase for tryptophan biosynthesis S
SWF1 -2.90 -3.20 -3.00 Palmitoyltransferase; acts on various SNAREs NS
URE2 -2.75 -2.45 -2.95 Nitrogen catabolite repression transcriptional regulator S
STP1 -2.50 -3.10 -3.00 Transcription factor for amino acid permease genes S
YGR153W -2.50 -2.60 -2.60 Putative protein of unknown function  
YDR008C -2.30 -2.80 -3.10 Dubious ORF; partially overlaps TRP1 tryptophan biosynthetic enzyme  
SEC 66 -2.30 -2.60 -2.40 Subunit of Sec63 complex; involved in ER protein translocation  
YEL045C -2.20 -2.60 -2.40 Dubious ORF  
PDR1 -2.15 -2.25 -2.70 Transcriptional regulator of multidrug resistance genes S
SPT4 -2.00 -1.85 -1.95 Regulates Pol I and Pol II transcription S
IRS4 -1.75 -2.50 -2.00 Regulates phosphatidylinositol 4,5-bisphosphate levels and autophagy S
YKL077W -1.75 -1.45 -1.20 Putative protein of unknown function  
THP2 -1.65 -2.00 -2.50 Subunit of the THO complex; involved in transcription elongation S
YDR203W -1.60 -1.90 -2.20 Dubious ORF; partially overlaps RAV2  
ICE2 -1.50 -1.50 -2.20 Integral ER membrane protein  
TKL1 -1.50 -1.40 -1.70 Transketolase in the pentose phosphate pathway S
COG7 -1.50 -1.40 -1.40 Component of the COG golgi transport complex  
COX20 -1.45 -1.85 -2.05 Mitochondrial inner membrane protein  
IMG2 -1.40 -1.70 -2.60 Mitochondrial ribosomal protein of the large subunit  
YDR455C -1.40 -1.50 -1.30 Dubious ORF; partially overlaps NHX1  
URA2 -1.30 -1.40 -1.55 Involved in de novo biosynthesis of pyrimidines NS
SIW14 -1.30 -1.30 -1.30 Tyrosine phosphatase  
GYP1 -1.25 -1.55 -1.50 cis-golgi GTPase-activating protein (GAP) for the Rab family NS
YSP1 -1.25 -1.50 -1.75 Mitochondrial protein; potential role in programmed cell death S
YJL120W -1.25 -1.30 -1.35 Dubious ORF; partially overlaps RPE1  
CUE1 -1.20 -1.00 -1.15 ER membrane protein; regulates ubiquitination  
PBP1 -1.20 -0.90 -1.10 Component of glucose deprivation induced stress granules  
Fitness scores, defined as the normalized log2 ratio of strain growth in the presence versus absence of toxaphene, quantify the requirement of a gene for growth. The
confirmed column indicates whether the strain was confirmed as sensitive (S) or not sensitive (NS- a false positive) by growth curve assays. The DSSA used to identify
altered strain growth is semi-quantitative, as variations in individual strain growth along with initial deletion pool strain counts can impact relative log2 ratios. Table S2
contains a list of all mutants displaying altered growth in the functional screen.
doi: 10.1371/journal.pone.0081253.t001
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Table 2. Genes required for toxaphene tolerance and their associated GO or MIPS categories.
GO Biological Process p value Genes identified ka fb
mitochondrial respiratory chain complex IV biogenesis (GO:0097034) 3.14E-004 PET122, PET54, PET494 3 8
regulation of ER to Golgi vesicle-mediated transport (GO:0060628) 3.33E-004 UBP3, BRE5 2 2
transcription elongation from RNA polymerase II promoter (GO:0006368) 4.21E-004 DST1, SPT4, THP2, ELF1, CDC73, MFT1 6 54
Group I intron splicing (GO:0000372) 6.56E-004 PET54, CBP2, MRS1 3 10
aerobic respiration (GO:0009060) 8.16E-004 COX20, QCR9, QCR8, COQ9, COX11, MRPL51 6 61
response to arsenic-containing substance (GO:0046685) 8.90E-004 RPN4, GET3, TIM18 3 11
heme a biosynthetic process (GO:0006784) 9.87E-004 COX15, COX10 2 3
ribophagy (GO:0034517) 9.87E-004 UBP3, BRE5 2 3
aromatic amino acid family biosynthetic process (GO:0009073) 1.17E-003 ARO3, TRP4, ARO2 3 12
MIPS Functional Classification p value Genes identified ka fb
transcription elongation (11.02.03.01.04) 1.69E-005 DST1, SPT4, THP2, ELF1, CDC73, MFT1 6 31
aerobic respiration [02.13.03) 4.85E-004 COX20, QCR9, COX23, QCR8, COQ9, COX11, MRPL51 7 77
Strains exhibiting sensitivity to three doses of toxaphene in the functional screen were entered into FunSpec and analyzed for overrepresented biological attributes (see
Materials and Methods section). a Number of genes in category identified as sensitive to toxaphene. b Number of genes in GO or MIPS category.
doi: 10.1371/journal.pone.0081253.t002
Figure 2.  Biological attributes required for toxaphene tolerance are identified by network mapping.  Cytoscape was used to
map fitness scores (the ratio of the log2 hybridization signals between DMSO and toxaphene exposures) for toxaphene-sensitive
strains onto the Saccharomyces cerevisiae BioGRID interaction dataset. A subnetwork (n = 104) containing genetic and physical
interactions between the sensitive, non-sensitive, and essential genes was created and significantly overrepresented (p value cutoff
of 0.03) GO categories were identified. The green node color corresponds to the GO p-value while the node size correlates to the
number of genes in the category. Edge arrows indicate hierarchy of GO terms. Networks for various GO categories are shown,
where node color corresponds to deletion strain fitness score and edge defines the type of interaction between the genes.
doi: 10.1371/journal.pone.0081253.g002
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Figure 3.  Transcription elongation mutants are sensitive to toxaphene.  Growth curves for three independent cultures were
obtained for the indicated strains and toxaphene concentrations. Mutants with known defects in transcription elongation are
sensitive to toxaphene, including members of the THO, Paf1p, SAGA, and TREX-2 complexes. Additional mutants lacking genes
implicated in transcription elongation exhibit sensitivity as well. The AUC was calculated for each curve and is shown as a
percentage of the untreated strain. Statistical significance between the wild-type and mutant strains was calculated with Student's t-
test, where ***p<0.001, **p<0.01, and *p<0.05.
doi: 10.1371/journal.pone.0081253.g003
Figure 4.  Nitrogen utilization and aromatic amino acid synthesis genes are required for toxaphene tolerance.  The AUC
was calculated for strains treated with 640μM or 960μM toxaphene and expressed as a percentage of the AUC for the untreated
strain. Bars signify the mean and SE for three independent cultures.
doi: 10.1371/journal.pone.0081253.g004
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toxaphene (data not shown). Finally, we found toxaphene did
not affect strains deleted for URA2 or URA4, enzymes involved
in the de novo biosynthesis of pyrimidine ribonucleotides [30]
(data not shown). Collectively, these data suggest that
toxaphene's mechanism is not analogous to MPA/6-AU, i.e., it
does not alter nucleotide pools or target the IMPDH family of
enzymes.
Toxaphene does not affect transcription elongation
We next examined toxaphene's potential to obstruct
transcription elongation, reasoning that inhibition of this
process could still occur via a mechanism distinct from that of
MPA/6-AU. The GLAM assay has been developed to indirectly
examine defects in transcription elongation [20], using the
premise that mutants impaired in elongation are less able to
transcribe long versus short transcription units. The toxaphene-
sensitive transcription elongation mutants identified in this
study have previously exhibited low scores when assayed for
GLAM [20,25]. We measured the GLAM-ratios of acid
phosphatase activity for a long (PHO5-lacZ or PHO5-LAC4)
versus short transcription unit (PHO5) for BY4743 wild-type
cells in the presence or absence of toxaphene, but did not find
altered ratios upon toxaphene exposure (Figure 7A). Since
GLAM is an indirect measurement of transcription elongation
that may not recognize all transcription elongation defects, we
directly assessed RNA polymerase II elongation by performing
an RNA polymerase II processivity assay [15], where levels of
RNA polymerase II bound to different regions of a long gene
are measured. If transcription elongation were compromised
under toxaphene treatment, the profile of RNA polymerase II
would change in comparison to a non-treated sample, as seen
in the case of 6AU and most transcription elongation mutants
detected in this study [15]. However, the patterns of the
toxaphene-treated and DMSO-treated samples were very
similar, indicating that toxaphene does not affect RNA
polymerase II processivity during transcription elongation
(Figure 7B).
Discussion
While the complex mixture of chlorinated terpenes known as
toxaphene was once the most widely applied pesticide in the
United States, its congeners are now considered persistent,
bioaccumulative, and toxic. In 2004, these unfavorable
characteristics resulted in toxaphene's addition to the
Stockholm Convention on Persistent Organic Pollutants treaty
as a member of the original “dirty dozen” compounds
designated for international elimination or restriction. Those
Figure 5.  Toxaphene exhibits synergy with MPA and 4-NQO.  Growth curve assays were performed for three independent
cultures of the BY4743 wild-type strain with the indicated compounds. Both MPA (a transcription elongation inhibitor) and 4-NQO (a
genotoxicant) displayed synergy with toxaphene, while tunicamycin (an endoplasmic reticulum stressor) did not. Statistical
significance was determined with one-way ANOVA with a Tukey post-test. *** represents significance observed at p<0.001 between
both toxaphene/toxaphene+synergist and synergist/toxaphene+synergist comparisons.
doi: 10.1371/journal.pone.0081253.g005
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Figure 6.  Neither guanine nor uracil rescues toxaphene sensitivity of transcription elongation mutants.  Relative growth
ratios (treatment vs. control) to a GFP-expressing wild-type strain were obtained for three independent cultures and the means and
SEs are shown. One-way ANOVA followed by a Bonferroni post-test determined statistical significance. ***p<0.001 for wild-type/
mutant comparisons. (A) The toxaphene sensitivity of the thp2Δ strain cannot be rescued by guanine. YPD media was
supplemented with the indicated concentrations of guanine and toxaphene. (B) Uracil cannot reverse the toxaphene sensitivity of
the mft1Δ or thp2Δ strains. Uracil and toxaphene were added to YPD media at the indicated concentrations. The impact of
toxaphene on mft1Δ and thp2Δ was stronger in these relative growth experiments versus growth curve assays (see Figure 3). Most
likely, this is due to the competitive nature of the relative growth assays, where even in control experiments, deletions with intrinsic
growth defects are outcompeted by wild-type. Exposure to toxaphene likely magnified the relative growth defects between mft1Δ or
thp2Δ and the wild-type strain in this assay.
doi: 10.1371/journal.pone.0081253.g006
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most at risk for exposure include Arctic populations who eat
aquatic mammals and people consuming sport-caught fish
from the Great Lakes [2]. Although toxaphene has been linked
to diseases such as cancer and amyotrophic lateral sclerosis
[4-7], cellular and molecular toxicity data associated with
exposure are severely lacking.
To discover potential mechanisms of toxicity, we screened
the S. cerevisiae homozygous diploid non-essential deletion
mutant collection to identify strains with altered growth in the
presence of toxaphene. The majority of yeast genes confirmed
as required for toxaphene tolerance are implicated in
transcription elongation and associated processes (Figure 3),
with additional resistance genes involved in nutrient utilization,
drug transport, and various other cellular functions (Figures 4
and S1). Our results regarding nutrient utilization mutants are
congruous with a report in which the toxicity of toxaphene was
approximately 3-fold greater in rats fed a protein deficient diet
[34]. Both results point to a need of a fully functional catabolic
environment to resist toxaphene. Enrichment analyses
indicated aerobic respiration mutants were sensitive to
toxaphene (Table 2), which is consistent with toxaphene's
ability to inhibit ATPases [31-33]. However, this group of strains
was not studied to a large extent herein, as (1) the qcr8Δ strain
(which has an electron transport chain defect) was a false
positive (data not shown) and (2) most are petite and/or slow
growing, which causes inherent competitive fitness defects
during pool screens and may thus misinform further analyses.
Future studies may elucidate the effects, if any, of toxaphene
on aerobic respiration in yeast. The most sensitive strain
identified by DSSA (and confirmed by growth curve assays)
was pdr5Δ, which, not unexpectedly, lacks a drug resistance
transporter involved in detoxification (Figure S1). Many yeast
genes described in this study are conserved (Table 3) and may
thus play a role in human toxicity. As the technical toxaphene
mixture utilized in this investigation is comprised of hundreds of
related chlorinated compounds, the congener(s) responsible for
the observed toxic effects in yeast remain unknown. Moreover,
both human metabolism and environmental weathering of
toxaphene [3] may produce derivatives of differing toxicological
relevance than those present in the technical mixture.
Although various -omics approaches have been utilized to
examine the molecular effects of toxaphene, its mechanism(s)
of toxicity remain ambiguous and findings directly related to
transcription elongation have not been reported. Perhaps most
relevant to this study is a report indicating that toxaphene
altered expression of transcription termination genes in
largemouth bass (Mehinto et al., in preparation). Woo and Yum
[35] performed gene expression analyses in marine medaka,
showing that toxaphene affected regulation of cytoskeletal,
developmental, metabolic, nucleic acid/protein binding, and
signal transduction genes. Increased expression of
homocysteine methyltransferase, a zinc metalloenzyme
involved in the metabolism of various amino acids [35], may
indicate a link to the nutrient utilization genes described in this
study (Figure 4). Toxaphene perturbed hepatic expression of
one carbon metabolism and ribosomal biogenesis genes in
Figure 7.  Toxaphene does not inhibit transcription elongation.  (A) GLAM-ratios are not altered upon toxaphene treatment.
The acid phosphatase activity of long (PHO5-lacZ or PHO5-LAC4) versus short (PHO5) transcriptional units was measured and the
means and SE are shown for three independent experiments. The mft1Δ strain was used as a positive control. (B) Toxaphene does
not affect RNA processivity. Levels of RNA polymerase II bound to different regions of a long gene were measured by chromatin
immunoprecipitation.
doi: 10.1371/journal.pone.0081253.g007
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adult male largemouth bass [36], while another study in the
same organism could not establish changes in neuroendocrine
signaling or neurotransmitter synthesis transcripts [37].
Proteomic analyses in the livers of largemouth bass identified
differentially expressed proteins following toxaphene exposure,
including an ion channel, a component of the pentose
phosphate pathway, and a glutathione S-transferase [38].
Functional profiling in yeast has been performed with the
related organochlorine pesticide dieldrin, but its toxic
mechanism (altered leucine availability) is different from that of
toxaphene [16].
Toxaphene-sensitive mutants also experience growth
defects in MPA and 6-AU (for a comparison, see Table S3),
two compounds that diminish transcription elongation by
inhibiting GMP synthesis [26,27]. By decreasing nucleotide
availability, MPA and 6-AU reduce RNA polymerase II
elongation rate and processivity [15], with transcription
elongation mutant sensitivity ascribed to the deleterious
combination of transcriptional defects [39]. Although toxaphene
and MPA synergistically inhibit yeast growth (Figure 5), two
different elongation assays did not detect any effect of
toxaphene on transcription elongation (Figure 7), unlike results
seen with MPA and 6-AU [15]. Intriguingly, several toxaphene
tolerance genes, such as SAC3, SPT4, THP1, and those
encoding components of the THO complex, are associated with
other processes tightly coupled to transcription elongation,
such as mRNA processing, mRNA nuclear export, or
transcription-coupled nucleotide excision repair [23,40-44]. The
possibility that one of these cellular operations is required for
toxaphene resistance led us to examine mRNA export in
presence of toxaphene using in situ hybridization, however, our
findings were inconclusive (data not shown). Alternatively,
toxaphene sensitivity of transcription elongation mutants may
be attributed to defective expression of yet to be defined
toxaphene tolerance protein(s). This type of indirect effect
occurs in elongation mutants exhibiting sensitivity to the
nucleotide depleting compound 6-AU; these deletions cannot
sufficiently induce Imd2p, the protein that combats 6-AU
toxicity by restoring nucleotide levels [45].
By identifying mutants with altered growth in toxaphene, our
study advances understanding of the genetic requirements for
the toxaphene response in yeast. Despite evidence indicating
transcription elongation mutants exhibit sensitivity to
toxaphene, our data suggest toxaphene does not affect
transcription elongation itself. Instead, we propose toxaphene
tolerance requires a yet to be identified cellular process closely
associated with transcription elongation, as toxaphene
synergism with MPA indicates a likely effect along this
pathway. Using data provided in this study, further pathway-
specific investigations in yeast or humans may elucidate the
distinct mechanism of toxaphene toxicity.
Supporting Information
Figure S1.  Additional genes required for toxaphene
tolerance. The area under the curve (AUC) was calculated for
strains treated with 640μM or 960μM toxaphene and expressed
as a percentage of the AUC for the untreated strain. All bars
represent the mean and SE for three independent cultures. (A)
Mutants lacking drug resistance genes are sensitive to
toxaphene. (B) Various mutants were confirmed to display
sensitivity to toxaphene.
(TIF)
Table S1.  Primers utilized in transcription elongation
assays. Primer sequences are listed.
(PDF)
Table S2.  Mutants displaying altered growth in toxaphene.
DSSA identified strains sensitive or resistant to various doses
of toxaphene. A negative log2 value signifies sensitivity at the
Table 3. Human orthologs of yeast genes required for toxaphene tolerance.
Yeast gene Human ortholog(s) Human protein description
CDC73 CDC73 Tumor suppressor; involved in transcriptional/post-transcriptional pathways
DST1 TCEA1 Transcription elongation factor A (SII)
HXK2 HK2 Hexokinase 2
IRA2 NF1 Neurofibromin 1, tumor suppressor
PDR5 ABCG2 ATP-binding cassette protein
RAD6 UBE2A/UBE2B Ubiquitin-conjugating enzyme E2A
RPB9 POLR2I DNA-directed RNA pol. II subunit RPB9
RTF1 RTF1 Role in transcription-coupled histone modification
SAC3 GANP Synonym MCM3AP, minichromosome maintenance protein 3
SPT4 SUPT4H1 Regulates mRNA processing and transcription elongation by RNA pol. II
STP1 ZNFN1A4 Zinc finger protein, subfamily 1A, 4 (Eos)
THO2 THOC2 Component of the THO subcomplex of the TREX complex
THP1 PCID2 PCI domain containing 2
TKL1 TKTL1/2, TKT Transketolase
UBP3 USP10 Ubiquitin specific peptidase 10
Deletion of any of these yeast genes caused sensitivity to toxaphene (listed in alphabetical order).
doi: 10.1371/journal.pone.0081253.t003
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corresponding dose, while a positive log2 value signifies
resistance.
(XLS)
Table S3.  Mutants displaying sensitivity to both
toxaphene and MPA, 6-AU, or 4-NQO. A literature search
was conducted to identify overlapping mutant sensitivities
between toxaphene, the GMP synthesis inhibitors
mycophenolic acid (MPA) and 6-azauracil (6-AU), and the
model carcinogen 4-nitroquinoline-N-oxide (4-NQO).
(PDF)
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